アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。
Synthetic peptide within Human FKBP12 aa 1-100 (internal sequence). The exact sequence is proprietary.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
Our Abpromise guarantee covers the use of ab108420 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 12 kDa.|
|ICC/IF||1/50 - 1/100.|
Lane 1: Wild-type HAP1 whole cell lysate (20 µg)
Lane 2: FKBP12 knockout HAP1 whole cell lysate (20 µg)
Lane 3: SH-SY5Y whole cell lysate (20 µg)
Lane 4: Human brain whole cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab108420 observed at 12 kDa. Red - loading control, ab9484, observed at 37 kDa.
ab108420 was shown to recognize FKBP12 in wild-type HAP1 cells as signal was lost at the expected MW in FKBP12 knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and FKBP12 knockout samples were subjected to SDS-PAGE. Ab108420 and ab9484 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
ab108420 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"